利用因子H结合蛋白实现针对脑膜炎奈瑟菌的广谱疫苗保护
本文综述了B群脑膜炎球菌疫苗的研发历程,重点阐述因子H结合蛋白(FHbp)作为疫苗抗原的特性。现有MenB-4C和MenB-FHbp两种疫苗均含FHbp,FHbp特异性抗体可在各亚家族内提供广泛交叉保护,但亚家族间交叉保护有限,需纳入两个亚家族的脂化FHbp变异体以实现广谱覆盖。
要点
- FHbp是几乎所有脑膜炎球菌菌株表面的关键蛋白,为两种已上市MenB疫苗的共同抗原。
- FHbp特异性抗体在各亚家族内提供广泛交叉保护,但亚家族间交叉保护有限。
- 脂化FHbp的免疫应答交叉反应谱优于非脂化形式,广谱覆盖需含两亚家族脂化变异体。
核心结论
- 纳入两个FHbp亚家族的脂化FHbp变异体有望对表达广泛FHbp序列变异的致病性脑膜炎球菌提供广谱保护。
研究设计与样本
- 本文为综述,聚焦B群脑膜炎球菌病预防疫苗的研发,重点讨论FHbp抗原。
主要发现
- FHbp是两种已上市MenB疫苗(MenB-4C和MenB-FHbp)诱导杀菌抗体的主要靶点。
- FHbp特异性抗体可在各亚家族内提供广泛交叉保护,但亚家族间交叉保护有限。
- 脂化FHbp诱导的免疫应答交叉反应谱优于非脂化FHbp。
关键数值与推荐
- MenB-4C含非脂化B亚家族FHbp及其他抗原(Neisserial Heparin Binding Antigen、Neisserial adhesin A、外膜囊泡)。
- MenB-FHbp含A和B两个亚家族各自的脂化FHbp。
临床怎么用
- 选择或评估MenB疫苗时,应关注其FHbp亚家族组成及是否采用脂化形式以判断广谱保护潜力。
局限性
- 本文为综述,未报告原始研究数据或定量合并分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neisseria meningitidis, the causative agent of invasive meningococcal disease (IMD), is classified into different serogroups defined by their polysaccharide capsules. Meningococcal serogroups A, B, C, W, and Y are responsible for most IMD cases, with serogroup B (MenB) causing a substantial percentage of IMD cases in many regions. Vaccines using capsular polysaccharides conjugated to carrier proteins have been successfully developed for serogroups A, C, W, and Y. However, because the MenB capsular polysaccharide is poorly immunogenic, MenB vaccine development has focused on alternative antigens. The 2 currently available MenB vaccines (MenB-4C and MenB-FHbp) both include factor H binding protein (FHbp), a surface-exposed protein harboured by nearly all meningococcal isolates that is important for survival of the bacteria in human blood. MenB-4C contains a nonlipidated FHbp from subfamily B in addition to other antigens, including Neisserial Heparin Binding Antigen, Neisserial adhesin A, and outer membrane vesicles, whereas MenB-FHbp contains a lipidated FHbp from each subfamily (A and B). FHbp is highly immunogenic and a main target of bactericidal activity of antibodies elicited by both licensed MenB vaccines. FHbp is also an important vaccine component, in contrast to some other meningococcal antigens that may have limited cross-protection across strains, as FHbp-specific antibodies can provide broad cross-protection within each subfamily. Limited cross-protection between subfamilies necessitates the inclusion of FHbp variants from both subfamilies to achieve broad FHbp-based vaccine coverage. Additionally, immune responses to the lipidated form of FHbp have a superior cross-reactive profile to those elicited by the nonlipidated form. Taken together, the inclusion of lipidated FHbp variants from both FHbp subfamilies is expected to provide broad protection against the diverse disease-causing meningococcal strains expressing a wide range of FHbp sequence variants. This review describes the development of vaccines for MenB disease prevention, with a focus on the FHbp antigen.
引用
- Findlow J, Bayliss CD, Beernink PT, et al. Broad vaccine protection against Neisseria meningitidis using factor H binding protein. Vaccine. 2020. PMID: 32878710. doi:10.1016/j.vaccine.2020.08.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。